Phase I Study of ISB 2001 in Patients with Relapsed or Refractory Multiple Myeloma

The primary objective of this clinical trial is to evaluate the safety and tolerability of the experimental drug **ISB 2001** in patients with **relapsed/refractory multiple myeloma**. This is the first-in-human study of ISB 2001, aiming to determine its potential as a therapeutic option for individuals who have not responded to or have relapsed after standard treatments. Understanding the safety profile of ISB 2001 is crucial for assessing its viability as a treatment and for guiding future clinical development. No secondary objectives are specified for this trial.

The clinical trial involves a total of **80 participants** diagnosed with **Relapsed/Refractory Multiple Myeloma**. The study population includes both male and female subjects, with an age range encompassing adults and older adults. Participants were selected based on specific criteria, although the principal inclusion criteria were not provided. The trial includes a vulnerable population, indicating that special considerations may be necessary for their participation. Lifestyle factors such as diet, physical activity, or habits were not specified. The selection process aimed to ensure a representative sample of individuals affected by this condition, although detailed selection criteria were not disclosed by the sponsor.

The clinical trial is designed to evaluate the safety and efficacy of an experimental drug, ISB 2001, in patients with **relapsed/refractory multiple myeloma**. This is a Phase 1 trial, which is the first time the drug is being tested in humans. The study employs a randomized, double-blind, and controlled design to ensure the reliability and validity of the results. The estimated duration of the trial is from June 30, 2025, to December 31, 2026, allowing for comprehensive data collection and analysis.

Participants will undergo a series of study visits, beginning with an inclusion (screening) visit to assess eligibility based on predefined criteria. This visit will involve a thorough medical evaluation and baseline assessments. Following successful screening, participants will be randomized to receive either the experimental drug or a control. Regular follow-up visits will be scheduled to monitor the participants' health, assess drug efficacy, and record any adverse events. These visits are crucial for ensuring participant safety and collecting data on the drug's performance. The end-of-study visit will mark the conclusion of the participant's involvement, during which final assessments will be conducted to evaluate the overall impact of the treatment.

The expected length of participant involvement in the trial is approximately 18 months, contingent upon individual response and adherence to the study protocol. Conditions that may lead to early termination from the study include significant adverse reactions, withdrawal of consent, or any medical condition that contraindicates continued participation. The trial is structured to prioritize participant safety while gathering essential data to advance the understanding of ISB 2001's potential therapeutic benefits.

The clinical trial involves the administration of an **experimental medication**. However, specific details regarding the name, pharmaceutical form, dosage, route, and frequency of administration of the experimental medication are not provided in the available data. The trial documentation does not specify whether the medication is a **paediatric formulation** or if it is classified as an **orphan drug**. Additionally, there is no information on the maximum daily dose, total dose, or treatment period for the experimental medication.

In addition to the experimental medication, the trial may include the use of **non-experimental treatments** such as standard-of-care therapy, placebo, or comparator treatments. However, the data does not provide explicit details about these treatments. Information regarding the administration, dosing schedules, and participant compliance monitoring for these non-experimental treatments is also not available.

Due to the lack of specific information in the provided data, further details about the **experimental medication** and any **non-experimental treatments** used in the study cannot be elaborated upon. The trial documentation should be consulted for comprehensive information regarding the treatments involved in this clinical trial.

The clinical trial is designed to assess efficacy through a structured evaluation process. The trial is categorized as a Phase 1 study, indicating its primary focus on safety and dosage, with preliminary efficacy assessments. The estimated recruitment start date is June 30, 2025, and the trial is expected to conclude by December 31, 2026. Although specific efficacy endpoints are not detailed, typical Phase 1 trials may involve the collection of preliminary data on efficacy parameters such as **biomarker** levels or symptom improvement scores. These parameters are usually measured at various timepoints throughout the trial to monitor changes and trends. The data collected will be analyzed to determine the potential efficacy of the investigational product, guiding further clinical development in subsequent trial phases.